HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

Nicolas Jacquelot 1, 2 Cyril Seillet 1, 3 Minyu Wang 4, 3 Angela Pizzolla 4, 3 Yang Liao 1, 3, 5, 6 Soroor Hediyeh-Zadeh 1, 3 Sharon Grisaru-Tal 7 Cynthia Louis 1, 3 Qiutong Huang 1, 3, 8 Jaring Schreuder 8 Fernando Souza-Fonseca-Guimaraes 8 Carolyn de Graaf 1, 3 Kevin Thia 4 Sean Macdonald 4 Mary Camilleri 1, 3 Kylie Luong 1, 3 Shengbo Zhang 1, 3 Michael Chopin 1, 3 Tristan Molden-Hauer 4 Stephen Nutt 1, 3 Viktor Umansky 9, 10 Bogoljub Ciric 11 Joanna Groom 1, 3 Paul Foster 12 Philip Hansbro 12, 13, 14 Andrew Mckenzie 15 Daniel Gray 1, 3 Andreas Behren 5, 6, 3 Jonathan Cebon 5, 6, 3, 16 Eric Vivier 17, 18, 19 Ian Wicks 1, 3 Joseph Trapani 4, 3 Ariel Munitz 7 Melissa Davis 1, 3 Wei Shi 1, 5, 6, 3 Paul Neeson 3, 4 Gabrielle Belz 1, 3, 8
Abstract : Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2s are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor, which coordinates the recruitment and activation of eosinophils to enhance antitumor responses. Tumor-infiltrating ILC2s expressed programmed cell death protein-1, which limited their intratumoral accumulation, proliferation and antitumor effector functions. This inhibition could be overcome in vivo by combining interleukin-33-driven ILC2 activation with programmed cell death protein-1 blockade to significantly increase antitumor responses. Together, our results identified ILC2s as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for antitumor immunotherapies.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03566011
Contributor : Anita Dumenil Connect in order to contact the contributor
Submitted on : Friday, February 11, 2022 - 12:19:47 PM
Last modification on : Friday, April 1, 2022 - 3:54:18 AM

Links full text

Identifiers

Collections

Citation

Nicolas Jacquelot, Cyril Seillet, Minyu Wang, Angela Pizzolla, Yang Liao, et al.. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nature Immunology, Nature Publishing Group, 2021, 22 (7), pp.851-864. ⟨10.1038/s41590-021-00943-z⟩. ⟨hal-03566011⟩

Share

Metrics

Record views

9